Cargando…

Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation

With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xi, Ren, Jie, Ma, Yinghe, Liu, Hongting, Rong, Quanjin, Feng, Yifan, Wang, Yameng, Cheng, Yu, Ge, Ruijia, Li, Zhiyu, Bian, Jinlei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327983/
https://www.ncbi.nlm.nih.gov/pubmed/30734612
http://dx.doi.org/10.1080/14756366.2018.1480614
_version_ 1783386575902605312
author Xu, Xi
Ren, Jie
Ma, Yinghe
Liu, Hongting
Rong, Quanjin
Feng, Yifan
Wang, Yameng
Cheng, Yu
Ge, Ruijia
Li, Zhiyu
Bian, Jinlei
author_facet Xu, Xi
Ren, Jie
Ma, Yinghe
Liu, Hongting
Rong, Quanjin
Feng, Yifan
Wang, Yameng
Cheng, Yu
Ge, Ruijia
Li, Zhiyu
Bian, Jinlei
author_sort Xu, Xi
collection PubMed
description With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine scaffold, showed good IDO1 inhibitory activity. To discover more compounds with similar structures to LVS-019, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivatives. Molecular docking studies suggested a possible binding mode of LVS-019, which provides a good starting point for the development of cyanopyridine scaffold compounds as potent IDO1 inhibitor. To improve potency of these hits, we further designed and synthesised another 14 derivatives of LVS-019. Among these compounds, LBJ-10 showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analogue. LBJ-10 can serve as ideal leads for further modifications as IDO1 inhibitors for cancer treatment.
format Online
Article
Text
id pubmed-6327983
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-63279832019-01-16 Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation Xu, Xi Ren, Jie Ma, Yinghe Liu, Hongting Rong, Quanjin Feng, Yifan Wang, Yameng Cheng, Yu Ge, Ruijia Li, Zhiyu Bian, Jinlei J Enzyme Inhib Med Chem Research Paper With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine scaffold, showed good IDO1 inhibitory activity. To discover more compounds with similar structures to LVS-019, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivatives. Molecular docking studies suggested a possible binding mode of LVS-019, which provides a good starting point for the development of cyanopyridine scaffold compounds as potent IDO1 inhibitor. To improve potency of these hits, we further designed and synthesised another 14 derivatives of LVS-019. Among these compounds, LBJ-10 showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analogue. LBJ-10 can serve as ideal leads for further modifications as IDO1 inhibitors for cancer treatment. Taylor & Francis 2019-01-02 /pmc/articles/PMC6327983/ /pubmed/30734612 http://dx.doi.org/10.1080/14756366.2018.1480614 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Xu, Xi
Ren, Jie
Ma, Yinghe
Liu, Hongting
Rong, Quanjin
Feng, Yifan
Wang, Yameng
Cheng, Yu
Ge, Ruijia
Li, Zhiyu
Bian, Jinlei
Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
title Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
title_full Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
title_fullStr Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
title_full_unstemmed Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
title_short Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
title_sort discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (ido1) inhibitors through virtual screening and preliminary hit optimisation
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327983/
https://www.ncbi.nlm.nih.gov/pubmed/30734612
http://dx.doi.org/10.1080/14756366.2018.1480614
work_keys_str_mv AT xuxi discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation
AT renjie discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation
AT mayinghe discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation
AT liuhongting discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation
AT rongquanjin discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation
AT fengyifan discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation
AT wangyameng discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation
AT chengyu discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation
AT geruijia discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation
AT lizhiyu discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation
AT bianjinlei discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation